208 related articles for article (PubMed ID: 19287950)
1. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma.
Yu M; Ohira M; Li Y; Niizuma H; Oo ML; Zhu Y; Ozaki T; Isogai E; Nakamura Y; Koda T; Oba S; Yu B; Nakagawara A
Int J Oncol; 2009 Apr; 34(4):931-8. PubMed ID: 19287950
[TBL] [Abstract][Full Text] [Related]
2. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
[TBL] [Abstract][Full Text] [Related]
3. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
4. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
[TBL] [Abstract][Full Text] [Related]
6. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24.
Abel F; Ejeskär K; Kogner P; Martinsson T
Br J Cancer; 1999 Dec; 81(8):1402-9. PubMed ID: 10604740
[TBL] [Abstract][Full Text] [Related]
7. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation.
Ando K; Ohira M; Ozaki T; Nakagawa A; Akazawa K; Suenaga Y; Nakamura Y; Koda T; Kamijo T; Murakami Y; Nakagawara A
Int J Cancer; 2008 Nov; 123(9):2087-94. PubMed ID: 18726896
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients.
Qi P; Xu MD; Ni SJ; Shen XH; Wei P; Huang D; Tan C; Sheng WQ; Zhou XY; Du X
Mol Carcinog; 2015 Sep; 54(9):742-50. PubMed ID: 24519959
[TBL] [Abstract][Full Text] [Related]
9. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
[TBL] [Abstract][Full Text] [Related]
10. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
[TBL] [Abstract][Full Text] [Related]
11. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.
Islam A; Kageyama H; Takada N; Kawamoto T; Takayasu H; Isogai E; Ohira M; Hashizume K; Kobayashi H; Kaneko Y; Nakagawara A
Oncogene; 2000 Feb; 19(5):617-23. PubMed ID: 10698506
[TBL] [Abstract][Full Text] [Related]
12. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
[TBL] [Abstract][Full Text] [Related]
13. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.
Wolf M; Korja M; Karhu R; Edgren H; Kilpinen S; Ojala K; Mousses S; Kallioniemi A; Haapasalo H
BMC Cancer; 2010 May; 10():181. PubMed ID: 20444257
[TBL] [Abstract][Full Text] [Related]
14. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
15. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group.
Bown N; Lastowska M; Cotterill S; O'Neill S; Ellershaw C; Roberts P; Lewis I; Pearson AD;
Med Pediatr Oncol; 2001 Jan; 36(1):14-9. PubMed ID: 11464868
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
Theissen J; Oberthuer A; Hombach A; Volland R; Hertwig F; Fischer M; Spitz R; Zapatka M; Brors B; Ortmann M; Simon T; Hero B; Berthold F
Genes Chromosomes Cancer; 2014 Aug; 53(8):639-49. PubMed ID: 24737690
[TBL] [Abstract][Full Text] [Related]
17. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
18. PPM1D is a potential target for 17q gain in neuroblastoma.
Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
[TBL] [Abstract][Full Text] [Related]
19. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
20. N-myc and noncoding RNAs in neuroblastoma.
Buechner J; Einvik C
Mol Cancer Res; 2012 Oct; 10(10):1243-53. PubMed ID: 22936790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]